List of Tables
Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2017 24
Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age 29
Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age 29
Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults 30
Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016 31
Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016 32
Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016 32
Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016 34
Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016 37
Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016 39
Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2017 43
Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2017 45
Table 13: Respiratory Disorders Therapeutics Market 47
Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Xolair, 2017 49
Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2017 50
Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmicort, 2017 51
Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Orkambi, 2017 52
Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Relvar/Breo Ellipta, 2017 54
Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2017 55
Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2017 57
Table 21: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2017 59
Table 22: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023 93
Table 23: Respiratory Disorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2017 96
Table 24: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006–2017 126
Table 25: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006–2017 136